In the 1970s, a school teacher who was concerned about his student’s lack of focus and energy wondered if his students would benefit from eating nutrient-dense algae. Inspired by the idea, the teacher began experimenting with a natural growing freshwater plant known as Aphanizomenon flos-aquae (AFA). Those who tried the AFA reported remarkable benefits.

The multitude of reports touting the results experienced by consumers of AFA helped sales of the botanical soar. However, the secret to the plant’s wide range of benefits had yet to be revealed.

Christian Drapeau arrived on the AFA scene in the 1990s. As a botanical researcher and neurophysiologist, Christian was asked to research the science behind what currently equated to speculation about the benefits of AFA.

With the support of his research team, Christian began experimenting with the botanical. Soon thereafter, the scientific community reported findings revealing that AFA contained specific molecules that supported various aspects of human health. Yet, many of the plant’s benefits remained unexplained.

Inspired by new developments in adult stem cell research, Christian was struck with a novel idea - what if AFA was somehow supporting the body in naturally releasing more stem cells?

Motivated by the new challenge, the research team went into high gear. More than 150 experiments later, Christian and his team experienced a breakthrough. At last, they had isolated the unique components responsible for AFA’s benefits.

Based on this extraordinary discovery, Christian developed a proprietary blend of AFA concentrates that offered consumers a practical method of taking advantage of the botanical’s health benefits in the form of a supplement. His next feat would include bringing the product to the global market.

With a unique product in his possession, Christian needed a business partner that shared his passion for adult stem cell nutrition and his vision for the future. He found such a partner in Ray Carter, a seasoned business entrepreneur. Christian and Ray worked tirelessly to form Stemtech, launching the company with a single product made from the unique blend of AFA concentrates – StemEnhance^®.

With the launch of StemEnhance, Stemtech grows exponentially. Growth is partially fueled by a groundbreaking clinical study published in the highly respected journal, Cardiovascular Revascularization Medicine. This study helps to define Stemtech as the leader of the adult stem cell nutrition industry.

With its network marketing business model in full effect, sales of Stemtech products begin to boom. Worldwide demand for StemEnhance encourages global expansion and Stemtech opens offices in more than a dozen countries on six continents.

2009 proved to be a big year for Stemtech. In addition to establishing a solid reputation as the global leader in adult stem cell nutrition, Stemtech was chosen as one of three finalists for the US Direct Selling Association’s prestigious Rising Star award.

Following industry wide accolades a year earlier, Stemtech received national recognition in 2010 by making Inc.’s coveted Inc. 5,000 list of fastest-growing privately held companies in America (ranked 1,484 out of over 29 million companies).

SE2^® Advanced Adult Stem Support is launched! Longer-lasting formula. Supports the release of MORE adult stem cells. This patent-pending, proprietary, all-natural health advancement supports the body’s natural renewal system to help the body maintain and repair tissue and organs.

DermaStem^® Renewal Serum does what no other skincare product can. Revolutionary, all-natural, revitalizes the skin at the cellular level to restore and maintain the skin’s youthful vibrance. Unveils brighter, smoother, younger-looking skin, starting in just 7 days.

2011 is a ground-breaking year for Stemtech. We are enjoying record sales in over 20 countries and are proud to see our growing family of Distributors achieving success around the world.

Stemtech applauds the Nobel Committee’s selection of stem cell researchers John Gurdon of Great Britain and Shinya Yamanaka of Japan for the 2012 Prize in physiology and medicine.

In experiments spanning over a 50-year period, Gurdon and Yamanaka “have revolutionized our understanding of how stem cells and organisms develop,” the Committee said in its announcement.

Stemtech’s President and CEO Ray C. Carter, Jr., said, “The award of this Nobel Prize further supports the recent momentum that sees adult stem cells as the most credible and promising answer to the major health challenges of our time.”

2013 was hailed “The Year of the Stem Cell” by The Atlantic. Another publication, Popular Science followed suit shortly after, both pointing out that great strides in stem cell science are being made now thus giving more people access to stem cell related health technologies.

On March 1, 2013, Stemtech launched a major campaign “Stem Cells for All” to help educate the world about stem cells and support the growing awareness.